CORAL SPRINGS, Florida, May 25, 2016 /PRNewswire/ --
As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward.According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
In breaking marijuana products & license advancements in the markets today: Freedom Leaf, Inc. (OTC: FRLF) is proud to announce the international expansion of its print and multimedia platform, as well as its portfolio of products and services in the Netherlands. Freedom Leaf, Inc. has entered into an International License Agreement secured by a $25,000 non-refundable deposit for the exclusive license to use the Freedom Leaf Brand with the right to publish the Freedom Leaf magazine in Dutch offering Advertising, while also undertaking Public Relations, Business Consulting, Branding Services, Business Development and Incubation for the Cannabis companies in the Netherlands. Freedom Leaf, Netherlands will also distribute branded products and services and will identify emerging opportunities to bring under the Freedom Leaf umbrella in the US and the Netherlands.
Read the full Freedom Leaf (FRLF) Press Release http://www.financialnewsmedia.com/profiles/frlf.html
Mr. Mario Louis Sylvester Lap is the Managing member of Freedom Leaf, Netherlands, bv. Mr Lap is a graduate from Open Universiteit Nederland, BS, Law and currently has affiliations with the following organizations: Drugtext Foundation, Foundation on Drug Policy and Human Rights & MLS LAP bv, RJM and MJR Holding Companies. 45 year Marijuana Legalization Activist and Freedom Leaf co-founder. Mr Richard C Cowan speaks about his relationship, "I have known Mario Lap for over twenty years, and there is no one in Europe who knows the drug reform world better than Mario."
In other Legal Marijuana / Cannabis / Cannabidol News and Developments in the markets: Insys Therapeutics, Inc. (NASDAQ: INSY) announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy. In this trial, 61 subjects with refractory epilepsy, between the ages of 1 year to 17 years, received treatment with Insys' pharmaceutical cannabidiol (CBD) oral solution across multiple investigative sites in the United States. The clinical trial evaluated multiple ascending doses of Insys' CBD with three cohorts of subjects receiving total daily doses of 10 mg/kg, 20 mg/kg or 40 mg/kg. Over 80% of these subjects continue to receive CBD in an ongoing long-term safety study.
84% support medical marijuana - If you thought full legalization support was high, you haven't seen anything yet. Based on a CBS News poll conducted in April 2015, 84% of those surveyed wanted to see marijuana legalized for medicinal use nationwide. It's not hard to understand why, either, with companies like GW Pharmaceuticals (NASDAQ: GWPH) showcasing the many uses of cannabinoids in early- and mid-stage clinical trials. For instance, GW Pharmaceuticals' Epidiolex helped reduced seizure frequency by more than 50% in two midstage studies for childhood-onset epilepsy in Dravet syndrome and Lennox-Gastaut syndrome. Read the full Article at http://www.fool.com/investing/general/2016/05/22/9-fast-facts-about-marijuana-including-1-telling-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
Terra Tech Corp. (OTC: TRTC), recently announced that its subsidiary, Edible Garden, a retail seller of locally grown hydroponic produce, herbs, and floral products, has shipped its first order of nutritionally-enhanced lettuce to ShopRite Supermarkets. The lettuce was developed in partnership with Nutrasorb LLC under the name SUPERLEAF™, in conjunction with Rutgers University, and is the latest addition to Edible Garden's product line of non-GMO fruits and vegetables.
Medical Marijuana, Inc. (OTC: MJNA) is pleased to announce that its hemp biotech investment, AXIM Biotechnologies, Inc. (AXIM), has begun the world's first human dermatological clinical trials on psoriasis (PsO) and atopic dermatitis (AD) commonly known as eczema based on AXIM's AX-1602 proprietary, patent-pending topical ointment formulation containing cannabigerol (CBG) and other cannabinoids. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands. Psoriasis and eczema are estimated to affect nearly 200 million people worldwide by 2024 with combined market estimates at $16 billion by 2022.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on Facebook: facebook.com/financialnewsmedia and Twitter: twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated three thousand five hundred dollars for news coverage of the current press release issued by Freedom Leaf, Inc. by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC